New developments in the treatment of castration resistant prostate cancer

por Wadia, Roxanne, Petrylak, Daniel P
Publicado 2014

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib

por Petrylak, Daniel P., Watkins, Simon P., Loehr, Andrea
Publicado 2022

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

por Wang, Zechen, Muthusamy, Viswanathan, Petrylak, Daniel P., Anderson, Karen S.
Publicado 2023

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility

por Crawford, E. David, Shore, Neal D., Petrylak, Daniel P., Higano, Celestia S., Ryan, Charles J.
Publicado 2017

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens

por Kibel, Adam S, Inman, Brant A, Pachynski, Russell K, Vu, Tuyen, Sheikh, Nadeem A, Petrylak, Daniel P
Publicado 2021

The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer

por Daniele, Bruno, Sangro, Bruno, Petrylak, Daniel, Calabrò, Fabio, Cartenì, Giacomo, Montesarchio, Vincenzo, De Placido, Sabino, Ascierto, Paolo A.
Publicado 2016

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advance...

por Matsubara, Nobuaki, Yonese, Junji, Kojima, Takahiro, Azuma, Haruhito, Matsumoto, Hiroaki, Powles, Thomas, Rosenberg, Jonathan E., Petrylak, Daniel P., Matsangou, Maria, Wu, Chunzhang, Campbell, Mary, Yamashiro, Mayumi
Publicado 2022

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castrati...

por Drake, Charles G, Quinn, David, Dreicer, Robert, Antonarakis, Emmanuel, Shore, Neal, Corman, John, Concepcion, Raoul, Pieczonka, Christopher, Campogan, Dwayne, Fan, Li-Qun, Chang, Nancy, Sheikh, Nadeem, Petrylak, Daniel
Publicado 2015

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RAN...

por Necchi, Andrea, Nishiyama, Hiroyuki, Matsubara, Nobuaki, Lee, Jae-Lyun, Petrylak, Daniel P., de Wit, Ronald, Drakaki, Alexandra, Liepa, Astra M., Mao, Huzhang, Bell-McGuinn, Katherine, Powles, Thomas
Publicado 2020

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

por Antonarakis, Emmanuel S., Subudhi, Sumit K., Pieczonka, Christopher M., Karsh, Lawrence I., Quinn, David I., Hafron, Jason M., Wilfehrt, Helen M., Harmon, Matthew, Sheikh, Nadeem A., Shore, Neal D., Petrylak, Daniel P.
Publicado 2023

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

por Sheikh, Nadeem A., Petrylak, Daniel, Kantoff, Philip W., dela Rosa, Corazon, Stewart, Frances P., Kuan, Ling-Yu, Whitmore, James B., Trager, James B., Poehlein, Christian H., Frohlich, Mark W., Urdal, David L.
Publicado 2012

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

por Armstrong, Andrew J., Szmulewitz, Russell Z., Petrylak, Daniel P., Holzbeierlein, Jeffrey, Villers, Arnauld, Azad, Arun, Alcaraz, Antonio, Alekseev, Boris, Iguchi, Taro, Shore, Neal D., Rosbrook, Brad, Sugg, Jennifer, Baron, Benoit, Chen, Lucy, Stenzl, Arnulf
Publicado 2019

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

por Fong, Lawrence, Morris, Michael J., Sartor, Oliver, Higano, Celestia S., Pagliaro, Lance, Alva, Ajjai, Appleman, Leonard J., Tan, Winston, Vaishampayan, Ulka, Porcu, Raphaelle, Tayama, Darren, Kadel, Edward E., Yuen, Kobe C., Datye, Asim, Armstrong, Andrew J., Petrylak, Daniel P.
Publicado 2021

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

por Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Publicado 2014

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

por Armstrong, Andrew J., Azad, Arun A., Iguchi, Taro, Szmulewitz, Russell Z., Petrylak, Daniel P., Holzbeierlein, Jeffrey, Villers, Arnauld, Alcaraz, Antonio, Alekseev, Boris, Shore, Neal D., Gomez-Veiga, Francisco, Rosbrook, Brad, Zohren, Fabian, Yamada, Shunsuke, Haas, Gabriel P., Stenzl, Arnulf
Publicado 2022

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

por Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Publicado 2019

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

por Lyou, Yung, Rosenberg, Jonathan E., Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel, Galsky, Matthew, Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard, Rearden, Jessica, Li, Ai, Xu, Cindy, Andresen, Corina, Moran, Susan, Daneshmand, Siamak, Bajorin, Dean, Pal, Sumanta K., Grivas, Petros
Publicado 2022

Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer

por Motamedinia, Piruz, Scott, Anna N., Bate, Kendall L., Sadeghi, Neda, Salazar, Guillermo, Shapiro, Edan, Ahn, Jennifer, Lipsky, Michael, Lin, James, Hruby, Greg W., Badani, Ketan K., Petrylak, Daniel P., Benson, Mitchell C., Donovan, Michael J., Comper, Wayne D., McKiernan, James M., Russo, Leileata M.
Publicado 2016

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhi...

por Tagawa, Scott T., Balar, Arjun V., Petrylak, Daniel P., Kalebasty, Arash Rezazadeh, Loriot, Yohann, Fléchon, Aude, Jain, Rohit K., Agarwal, Neeraj, Bupathi, Manojkumar, Barthelemy, Philippe, Beuzeboc, Philippe, Palmbos, Phillip, Kyriakopoulos, Christos E., Pouessel, Damien, Sternberg, Cora N., Hong, Quan, Goswami, Trishna, Itri, Loretta M., Grivas, Petros
Publicado 2021

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

por Kamat, Ashish M., Bellmunt, Joaquim, Galsky, Matthew D., Konety, Badrinath R., Lamm, Donald L., Langham, David, Lee, Cheryl T., Milowsky, Matthew I., O’Donnell, Michael A., O’Donnell, Peter H., Petrylak, Daniel P., Sharma, Padmanee, Skinner, Eila C., Sonpavde, Guru, Taylor, John A., Abraham, Prasanth, Rosenberg, Jonathan E.
Publicado 2017